TY - JOUR
T1 - EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer
T2 - A secondary analysis of RTOG 0324
AU - Komaki, Ritsuko
AU - Paulus, Rebecca
AU - Blumenschein, George R.
AU - Curran, Walter J.
AU - Robert, Francisco
AU - Thariat, Juliette
AU - Werner-Wasik, Maria
AU - Choy, Hak
AU - Hirsch, Fred R.
AU - Ang, Kie Kian
N1 - Publisher Copyright:
© 2014 Elsevier Ireland Ltd. All rights reserved.
PY - 2014/7/1
Y1 - 2014/7/1
N2 - Purpose: We investigated whether expression of epidermal growth factor receptor (EGFR) was associated with survival and disease control in this secondary analysis of a phase II trial of cetuximab + chemoradiation for stage III non-small cell lung cancer. Methods: Patients received cetuximab weekly before and during radiation (63 Gy/35 fractions/7 weeks) with weekly carboplatin + paclitaxel. We analyzed EGFR expression by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in pretreatment biopsy specimens and compared findings with overall and progression-free survival (OS, PFS) and time to progression (TTP). Results: Specimens for IHC and FISH were collected from 51 and 45 of 87 evaluable patients. Pretreatment characteristics did not differ for patients with (n = 51) or without (n = 36) EGFR IHC data, or with (n = 45) or without (n = 42) FISH data. However, patients without IHC data had worse OS (HR = 1.63, P = 0.05), worse PFS (HR = 1.88, P = 0.008), and worse TTP [HR = 1.99, P = 0.01] than those with IHC data. EGFR protein expression was not related to pretreatment characteristics or OS; FISH-positive disease was associated with better performance status but not with OS, PFS, or TTP. Conclusions: Surprisingly, outcomes differed not by EGFR expression but by the availability of samples for analysis, underscoring the importance of obtaining biopsy samples in such trials.
AB - Purpose: We investigated whether expression of epidermal growth factor receptor (EGFR) was associated with survival and disease control in this secondary analysis of a phase II trial of cetuximab + chemoradiation for stage III non-small cell lung cancer. Methods: Patients received cetuximab weekly before and during radiation (63 Gy/35 fractions/7 weeks) with weekly carboplatin + paclitaxel. We analyzed EGFR expression by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in pretreatment biopsy specimens and compared findings with overall and progression-free survival (OS, PFS) and time to progression (TTP). Results: Specimens for IHC and FISH were collected from 51 and 45 of 87 evaluable patients. Pretreatment characteristics did not differ for patients with (n = 51) or without (n = 36) EGFR IHC data, or with (n = 45) or without (n = 42) FISH data. However, patients without IHC data had worse OS (HR = 1.63, P = 0.05), worse PFS (HR = 1.88, P = 0.008), and worse TTP [HR = 1.99, P = 0.01] than those with IHC data. EGFR protein expression was not related to pretreatment characteristics or OS; FISH-positive disease was associated with better performance status but not with OS, PFS, or TTP. Conclusions: Surprisingly, outcomes differed not by EGFR expression but by the availability of samples for analysis, underscoring the importance of obtaining biopsy samples in such trials.
KW - Cetuximab
KW - Clinical trials identifier NCT00081302
KW - Erbitux
KW - Inoperable lung cancer
KW - RTOG 0324
UR - http://www.scopus.com/inward/record.url?scp=84908170897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908170897&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2014.06.012
DO - 10.1016/j.radonc.2014.06.012
M3 - Article
C2 - 25042878
AN - SCOPUS:84908170897
SN - 0167-8140
VL - 112
SP - 30
EP - 36
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 1
ER -